Mavyret FDA Approval History
Last updated by Judith Stewart, BPharm on Jan 28, 2021.
FDA Approved: Yes (First approved August 3, 2017)
Brand name: Mavyret
Generic name: glecaprevir and pibrentasvir
Dosage form: Tablets and Oral Pellets
Company: AbbVie Inc.
Treatment for: Hepatitis C
Mavyret (glecaprevir/pibrentasvir) is a fixed-dose combination of glecaprevir, an NS3/4A protease inhibitor, and pibrentasvir, an NS5A inhibitor, indicated for the treatment of all major genotypes (GT1-6) of chronic hepatitis C.
Development timeline for Mavyret
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.